Industry demands clarification of cost effectiveness criterion in making Medicare coverage decisions
This article was originally published in Clinica
The US Medical Device Manufacturers Association (MDMA) urged the Health Care Financing Administration (HCFA) to discuss at a public meeting the role of cost-effectiveness in making decisions on whether or not to cover a procedure under the Medicare health insurance programme for the elderly. HCFA held a meeting last September to discuss its proposals for coverage reform.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.